Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An announcement from PolyPid ( (PYPD) ) is now available.
On August 11, 2025, PolyPid Ltd. appointed Nir Dror as the Interim Chairman of the Board following the termination of Jacob Harel’s service. The company reported positive results from its Phase 3 SHIELD II trial for D-PLEX100, demonstrating significant efficacy in reducing surgical site infections, and plans to submit a New Drug Application in early 2026. PolyPid also strengthened its financial position through a successful warrant exercise and is advancing strategic partnerships to maximize market potential. The appointment of Dr. Nurit Tweezer-Zaks as Chief Medical Officer further bolsters the company’s leadership team as it prepares for commercialization.
The most recent analyst rating on (PYPD) stock is a Buy with a $14.00 price target. To see the full list of analyst forecasts on PolyPid stock, see the PYPD Stock Forecast page.
Spark’s Take on PYPD Stock
According to Spark, TipRanks’ AI Analyst, PYPD is a Neutral.
PolyPid’s score reflects significant financial challenges, including consistent losses and negative equity. While the company’s clinical advancements and financing efforts are promising, they are not sufficient to offset the financial risks. The stock exhibits neutral technical indicators and an unattractive valuation, limiting its appeal to investors.
To see Spark’s full report on PYPD stock, click here.
More about PolyPid
PolyPid Ltd. is a late-stage biopharma company focused on improving surgical outcomes through its proprietary PLEX technology, which enables controlled, prolonged-release therapeutics. The company’s lead product candidate, D-PLEX100, is aimed at preventing abdominal colorectal surgical site infections. PolyPid also has a pipeline targeting oncology, obesity, and diabetes.
Average Trading Volume: 517,084
Technical Sentiment Signal: Sell
Current Market Cap: $34.85M
Find detailed analytics on PYPD stock on TipRanks’ Stock Analysis page.